MedTrace Logo

Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)

NCT00575796 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-09-20

No results posted yet for this study

Summary

The overall objective of this study is to determine the efficacy of weekly Vinblastine in chemotherapy naïve patients with progressive or incompletely resected paediatric low grade glioma, to generate estimates of the response rate, progression-free survival, toxicity and quality of daily living among the population treated and determine biologic factors which will enable us to predict tumour behaviour.

Conditions

Interventions

DRUG

Vinblastine Sulphate

Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.

Sponsors & Collaborators

  • Pediatric Oncology Group of Ontario

    collaborator OTHER

  • Brain Tumour Program

    collaborator OTHER

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Ute Bartels, MD · The Hospital for Sick Children, Toronto Canada

  • Bruce Crooks, MD · IWK Health Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2018-10-31
Completion
2019-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00575796 on ClinicalTrials.gov